



## Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

April 24, 2024

*Company to host conference call and webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time*

SAN DIEGO--(BUSINESS WIRE)--Apr. 24, 2024-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.

The conference call will be available on Acadia's website, [Acadia.com](https://www.acadia.com) under the investors section and will be archived there until June 7, 2024. The conference call may also be accessed by registering for the call [here](#). Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

### *About Acadia Pharmaceuticals*

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at [Acadia.com](https://www.acadia.com) and follow us on [LinkedIn](#) and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240424882955/en/): <https://www.businesswire.com/news/home/20240424882955/en/>

### *Investor Contact:*

Acadia Pharmaceuticals Inc.

Al Kildani

(858) 261-2872

[ir@acadia-pharm.com](mailto:ir@acadia-pharm.com)

Acadia Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

[ir@acadia-pharm.com](mailto:ir@acadia-pharm.com)

Source: Acadia Pharmaceuticals Inc.